Patents by Inventor Geraldine Marcenyac

Geraldine Marcenyac has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Loratadine transdermal device and methods
    Patent number: 9259397
    Abstract: A tansdermal delivery device for effectively treating seasonal allergic rhinitis and chronic idiopathic urticariain in humans is disclosed and methods thereof.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: February 16, 2016
    Assignee: Purdue Pharma L.P.
    Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti Valia
  • DISPOSAL SYSTEM FOR TRANSDERMAL DOSAGE FORM
    Publication number: 20150182474
    Abstract: The present invention relates to a disposable article to prevent the misuse of a transdermal dosage form (FIG. 1(a)). The article is comprised of an outer layer (1) having an inner layer-facing side and an opposite side; an inner layer (3) having an outer layer-facing side and an opposite side, the inner layer (3) joined to the outer layer (1) to form one or more closed material reservoir (2) between the outer layer-facing side of the inner layer (2) and the inner layer-facing side of the outer layer (1); and adhesive (4) covering a first portion of the opposite side of the inner layer (3), wherein the adhesive (4) is a heat activated adhesive that changes color and/or is activated when the article is subjected to elevated temperatures, thereby sealing the transdermal dosage form within the article.
    Type: Application
    Filed: August 12, 2014
    Publication date: July 2, 2015
    Applicant: PURDUE PHARMA L.P.
    Inventors: Geraldine Marcenyac, Mark Alfonso, Lane Gehrlein, Stephen Howard, Lino Tavares, Ronald Greenbaum, Seth Levy, Benjamin Oshlack
  • Terazosin transdermal device and methods
    Patent number: 8496960
    Abstract: A method of effectively treating benign prostatic hypertension in humans is achieved by administering amorphous terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.
    Type: Grant
    Filed: October 23, 2002
    Date of Patent: July 30, 2013
    Assignee: Purdue Pharma L.P.
    Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti H. Valia
  • DISPOSAL SYSTEM FOR TRANSDERMAL DOSAGE FORM
    Publication number: 20080262284
    Abstract: The present invention relates to a disposable article to prevent the misuse of a transdermal dosage form (FIG. 1(a)). The article is comprised of an outer layer (1) having an inner layer-facing side and an opposite side; an inner layer (3) having an outer layer-facing side and an opposite side, the inner layer (3) joined to the outer layer (1) to form one or more closed material reservoir (2) between the outer layer-facing side of the inner layer (2) and the inner layer-facing side of the outer layer (1); and adhesive (4) covering a first portion of the opposite side of the inner layer (3), wherein the adhesive (4) is a heat activated adhesive that changes color and/or is activated when the article is subjected to elevated temperatures, thereby sealing the transdermal dosage form within the article.
    Type: Application
    Filed: June 27, 2008
    Publication date: October 23, 2008
    Applicant: PURDUE PHARMA L.P.
    Inventors: Geraldine Marcenyac, Mark Alfonso, Lane Gehrlein, Stephen Howard, Lino Tavares, Ronald Greenbaum, Seth Levy, Benjamin Oshlack
  • Felodipine transdermal device and methods
    Patent number: 7018649
    Abstract: A method of effectively treating hypertension in humans is achieved by administering felodipine via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours days, and preferably for about 3 to about 8 days.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: March 28, 2006
    Assignee: Euro-Celtique, S.A.
    Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti Valia
  • Terazosin transdermal device and methods
    Publication number: 20050064022
    Abstract: A method of effectively treating benign prostatic hypertension in humans is achieved by administering amorphous terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.
    Type: Application
    Filed: October 23, 2002
    Publication date: March 24, 2005
    Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti Valia
  • Terazosin transdermal device & methods
    Publication number: 20050031678
    Abstract: A method of effectively treating benign prostatic hypertension in humans is achieved by administering terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.
    Type: Application
    Filed: September 20, 2004
    Publication date: February 10, 2005
    Applicant: Euro-Celtique S.A
    Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti Valia
  • Disposal system for transdermal dosage form
    Publication number: 20040146547
    Abstract: The present invention relates to a disposable article to prevent the misuse of a transdermal dosage form (FIG. 1(a)). The article is comprised of an outer layer (1) having an inner layer-facing side and an opposite side; an inner layer (3) having an outer layer-facing side and an opposite side, the inner layer (3) joined to the outer layer (1) to form one or more closed material reservoir (2) between the outer layer-facing side of the inner layer (2) and the inner layer-facing side of the outer layer (1); and adhesive (4) covering a first portion of the opposite side of the inner layer (3), wherein the adhesive (4) is a heat activated adhesive that changes color and/or is activated when the article is subjected to elevated temperatures, thereby sealing the transdermal dosage form within the article.
    Type: Application
    Filed: November 20, 2003
    Publication date: July 29, 2004
    Inventors: Geraldine Marcenyac, Mark Alfonso, Lane Gehrlein, Stephen Howard, Lino Tavares, Ronald Greenbaum, Seth Levy, Benjamin Oshlack
  • Felodipine transdermal device and methods
    Publication number: 20030072791
    Abstract: A method of effectively treating hypertension in humans is achieved by administering felodipine via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours days, and preferably for about 3 to about 8 days.
    Type: Application
    Filed: October 23, 2001
    Publication date: April 17, 2003
    Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti H. Valia
  • Loratadine transdermal device and methods
    Publication number: 20030035828
    Abstract: A tansdermal delivery device for effectively treating seasonal allergic rhinitis and chronic idiopathic urticariain in humans is disclosed and methods thereof.
    Type: Application
    Filed: October 23, 2001
    Publication date: February 20, 2003
    Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti H. Valia
  • Terazosin transdermal device and methods
    Publication number: 20020198215
    Abstract: A method of effectively treating benign prostatic hypertension in humans is achieved by administering terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.
    Type: Application
    Filed: October 23, 2001
    Publication date: December 26, 2002
    Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti H. Valia